phd 1

PHD-1-IN-1 is a potent inhibitor of hypoxia-inducible factor prolylhydroxylase domain-1 (PHD-1) enzyme(IC50 = 0.034 μM).

HIF-PHD-IN-1 is a pharmacological compound that acts as an orally active inhibitor of the hypoxia-inducible factor prolyl hydroxylase domain (HIF-PHD), displaying an IC50 of 54 nM for hHIF-PHD2. Its potential as a therapeutic agent for renal anemia is highly promising.

PHD-IN-1 (compound 80) is a potent PHD2 inhibitor with an IC50 value of ≤5 nM and demonstrates EC50 values of 2.5 μM in EPO Elisa assays in both Caco2-HIF1a-HiBiT-clone-1 and Hep3B cell lines [1].

PhD1, an antimicrobial peptide originating from monkey leukocytes, exhibits efficacy against various bacteria and the fungus Candida albicans [1].

IOX2 (IOX 2) is a selective inhibitor of the Hypoxia Inducible Factor (HIF) Prolyl-Hydroxylases (PHD); active in cells with the IC50 value of 21 nM for PHD2 ELGN-1 and no inhibition at FIH (20uM).

Prolyl Hydroxylase inhibitor 1 is an orally active inhibitor of hypoxia inducible factor (HIF)-prolyl hydroxylase (PHD) (IC50 of 62.23 nM).

NV03 is a potent and selective antagonist of the UHRF1 (Ubiquitin-like with PHD and RING finger domains 1)-H3K9me3 interaction, binding to the UHRF1 tandem tudor domain with a Kd of 2.4 μM. NV03 holds potential as an anticancer therapeutic [1].

NVS-BPTF-1 is a specific inhibitor of bromodomain and PHD finger containing transcription factor (BPTF), exhibiting a dissociation constant (K_D) of 71 nM [1].

PHD-IN-2 (Compound 91), a potent PHD antagonist with an IC50 of less than 5 nM, effectively stimulates erythropoietin synthesis in HEP3B cells with an EC50 of less than 2.5 μM. It is applicable for research purposes across various medical fields, including cardiovascular, metabolic, hematological, pulmonary, kidney, liver, and wound healing disorders, as well as cancer [1].

HIF-PHD-IN-3 is a potent hiPSC-CM cardioprotective scaffold with potential inhibitory effects on HIF-PHD, regulates heme oxygenase-1, and can be used to study anaemia.

HDAC6 8 BRPF1-IN-1 is a dual inhibitor targeting HDAC6, HDAC8, and the bromodomain and PHD finger containing protein 1 (BRPF1). It exhibits inhibitory activity against HDAC1, HDAC6, and HDAC8 with IC50 values of 797 nM, 344 nM, and 908 nM, respectively, and inhibits BRPF1 with a Kd value of 175.2 nM. This compound is utilized in cancer research [1].

PHD-IN-3 (Compound 15), an orally active PHD inhibitor, is utilized in research related to anemia linked to chronic kidney disease [1].

JBC117, a novel anticancer lead compound targeting Pygo2 PHD, effectively antagonizes β-catenin-dependent cell activity, inhibits cancer cell migration and invasion, and induces apoptosis [1].

HIF-PHD-IN-2 (compound 25) is a highly effective PHD inhibitor with IC50 values below 100 nM for PHD1, PHD2, and PHD3 [1].

DC-BPi-11 hydrochloride is a BPTF (bromodomain PHD finger transcription factor) inhibitor with an IC50 value of 698 nM, demonstrating significant anti-proliferative effects on leukemia cells [1].